Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb - Nagusman Danil; Sharvianty Arifuddin; Eddy Hartono; Nur Rakhmah; Ajardiana Ajardiana; Syahrul Rauf; Andi Alfian Zainuddin (Dep/SMF Obstetri & Ginekologi Fakultas Kedokteran Universitas Padjadjaran, 2023)
Tujuan: Mengetahui perbandingan respon terapi dan toksisitas regimen kemoterapi kombinasi Paclitaxel Carboplatin Ifosfamide dengan Paclitaxel Carboplatin pada kanker serviks stadium IIB.Metode: Sebanyak 30 pasien yang baru terdiagnosis kanker serviks stadium IIB dibagi menjadi dua kelompok terapi kombinasi yaitu kelompok Paclitaxel-Carboplatin-Ifosfamide (TIP) dan Paclitaxel-Carboplatin (TP). Volume tumor dan respon terapi diukur sebelum dan sesudah tiga siklus kemoterapi.Hasil:Tingkat penurunan rata-rata volume tumor pada kelompok Paclitaxel-Carboplatin-Ifosfamide dan Paclitaxel-Carboplatin sebesar (23,66% vs 39,08%). Tidak ada perbedaan secara bermakna angka respon parsial, angka respon progresif dan tidak ada respon antara kelompok dengan Paclitaxel-Carboplatin-Ifosfamide dengan kelompok Paclitaxel-Carboplatin dengan p > 0,05. Hasil antara Paclitaxel-Carboplatin-Ifosfamide dan Paclitaxel-Carboplatin pada respon parsial (46,7 % vs 73,3%), respon progresif (13,3% vs 13.3%), dan tidak ada respon (40,0 % vs 1,3%) dan toksisitas kelas 2 lebih dominan pada kelompok Paclitaxel-Carboplatin-Ifosfamide yaitu mual, kerontokan (53,3%) dan fatique, muntah (46,7%).Kesimpulan: Regimen kemoterapi kombinasi Paclitaxel-Carboplatin lebih efektif dalam menurunkan ukuran tumor kanker serviks stadium IIB dengan efek samping yang lebih minimal dibandingkan kombinasi Paclitaxel-Carboplatin-Ifosfamide.Comparison of Therapy Response and Toxicity of Combination Chemotherapy Regimens Between Paclitaxel, Carboplatin And Ifosfamide (PCI) with Paclitaxel and Carboplatin (PC) in Stadium IIB Cervical CancerAbstractObjective: To compare the therapeutic response and toxicity of a combination chemotherapy regimen of Paclitaxel Carboplatin Ifosfamide with Paclitaxel Carboplatin in stage IIB cervical cancer. Methods: A total of 30 patients newly diagnosed with stage IIB cervical cancer were divided into two combination therapy groups, namely the Paclitaxel-Carboplatin-Ifosfamide (PCI) and Paclitaxel-Carboplatin (PC) groups. Tumor volume and clinical response were measured before and after three cycles. Result: The average reduction rate of tumor volume in the Paclitaxel-Carboplatin-Ifosfamide and Paclitaxel-Carboplatin groups was (23.66% vs 39.08%). There was no significant difference in the partial response rate, progressive response rate and no response between the Paclitaxel-Carboplatin-Ifosfamide group and the Paclitaxel-Carboplatin group with p > 0.05. Results between Paclitaxel-Carboplatin-Ifosfamide and Paclitaxel-Carboplatin on partial response (46.7% vs 73.3%), progressive response (13.3% vs 13.3%), and no response (40.0% vs 1, 3%) and class 2 toxicity was more dominant in the Paclitaxel-Carboplatin-Ifosfamide group namely nausea, hair loss (53.3%) and fatigue, vomiting (46.7%). Conclusion: The Paclitaxel-Carboplatin combination chemotherapy regimen is more effective in reducing the tumor size of stage IIB cervical cancer with lower side effects than the Paclitaxel-Carboplatin-Ifosfamide combination.Key words: cervical cancer, chemotherapy, side effects